Sanofi (EPA:SAN) received a €83.00 ($102.47) price objective from stock analysts at Berenberg Bank in a note issued to investors on Monday. The firm currently has a “neutral” rating on the stock. Berenberg Bank’s price objective indicates a potential upside of 25.43% from the company’s current price.
Other research analysts also recently issued research reports about the company. Deutsche Bank set a €93.00 ($114.81) target price on Sanofi and gave the stock a “buy” rating in a research note on Tuesday, January 30th. Kepler Capital Markets set a €83.00 ($102.47) target price on Sanofi and gave the stock a “buy” rating in a research note on Tuesday, February 6th. Societe Generale set a €100.00 ($123.46) target price on Sanofi and gave the stock a “buy” rating in a research note on Tuesday, January 23rd. Credit Suisse Group set a €95.00 ($117.28) target price on Sanofi and gave the stock a “buy” rating in a research note on Thursday, February 8th. Finally, Sanford C. Bernstein set a €82.00 ($101.23) target price on Sanofi and gave the stock a “neutral” rating in a research note on Wednesday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of €79.29 ($97.89).
Shares of EPA SAN opened at €66.17 ($81.69) on Monday. Sanofi has a 12 month low of €63.09 ($77.89) and a 12 month high of €92.97 ($114.78).
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3343037/berenberg-bank-analysts-give-sanofi-san-a-83-00-price-target.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.